Intrarater and interrater reliability of the MS functional composite outcome measure

被引:103
作者
Cohen, JA
Fischer, JS
Bolibrush, DM
Jak, AJ
Kniker, JE
Mertz, LA
Skaramagas, TT
Cutter, GR
机构
[1] Cleveland Clin Fdn, Mellen Ctr Multiple Sclerosis Treatment & Res U10, Dept Neurol, Cleveland, OH 44195 USA
[2] AMC Canc Ctr, Ctr Res Methodol & Biometr, Lakewood, CO USA
关键词
MS; clinical trials; outcome assessment; composite measure;
D O I
10.1212/WNL.54.4.802
中图分类号
R74 [神经病学与精神病学];
学科分类号
摘要
Objective: To assess practice effects, and intrarater and interrater reliability of the MS functional composite (MSFC) outcome measure. Background: To address the poor reliability and insensitivity to change of available MS clinical rating scales, the National MS Society's Clinical Outcomes Assessment Task Force developed the MSFC, a multidimensional quantitative clinical outcome measure that includes tests of leg function/ambulation (Timed 25-Foot Walk), arm function (Nine-Hole Peg Test), and cognitive function (Paced Auditory Serial Addition Test). Methods: Ten patients with secondary progressive MS underwent six testing sessions over a 2-week period. The MSFC was administered by the same examining technician in the first five sessions and by the other technician in the sixth, Patients were reassessed by both technicians after 6 months (sessions 7 and 8), The MSFC score was calculated as the mean of the Z scores of the three components. A pooled dataset derived from secondary progressive MS patients in the placebo arms of previous clinical trials and natural history studies served as the reference population to standardize scores. Results: Practice effects were evident initially but stabilized by the fourth administration. The intraclass correlation coefficient (ICC) was 0.97 for the MSFC for session 4 versus session 5 (intrarater reliability). The ICC was 0.95 for session 5 versus session 6 (interrater reliability), and was 0.96 for session 7 versus session 8 when patients were reassessed 6 months later, Conclusions: The MS functional composite (MSFC) outcome measure had excellent intrarater and interrater reliability when standardized procedures were used to train examining technicians and to assess patients. Prebaseline testing sessions should be included in clinical trials employing the MSFC to compensate for practice effects.
引用
收藏
页码:802 / 806
页数:5
相关论文
共 25 条
  • [1] INTERRATER RELIABILITY IN ASSESSING FUNCTIONAL-SYSTEMS AND DISABILITY ON THE KURTZKE SCALE IN MULTIPLE-SCLEROSIS
    AMATO, MP
    FRATIGLIONI, L
    GROPPI, C
    SIRACUSA, G
    AMADUCCI, L
    [J]. ARCHIVES OF NEUROLOGY, 1988, 45 (07) : 746 - 748
  • [2] AMATO MP, 1987, ITAL J NEUROL SCI S6, V3, P129
  • [3] Bever C T Jr, 1995, Mult Scler, V1, P165
  • [4] Development of a multiple sclerosis functional composite as a clinical trial outcome measure
    Cutter, GR
    Baier, ML
    Rudick, RA
    Cookfair, DL
    Fischer, JS
    Petkau, J
    Syndulko, K
    Weinshenker, BG
    Antel, JP
    Confavreux, C
    Ellison, GW
    Lublin, F
    Miller, AE
    Rao, SM
    Reingold, S
    Thompson, A
    Willoughby, E
    [J]. BRAIN, 1999, 122 : 871 - 882
  • [5] DEVELOPMENT AND EVALUATION OF CHIPASAT, AN ATTENTION TEST FOR CHILDREN .2. TEST-RETEST RELIABILITY AND PRACTICE EFFECT FOR A NORMAL SAMPLE
    DYCHE, GM
    JOHNSON, DA
    [J]. PERCEPTUAL AND MOTOR SKILLS, 1991, 72 (02) : 563 - 572
  • [6] Randomised double-blind placebo-controlled study of interferon β-1a in relapsing/remitting multiple sclerosis
    Ebers, GC
    Rice, G
    Lesaux, J
    Paty, D
    Oger, J
    Li, DKB
    Beall, S
    Devonshire, V
    Hashimoto, S
    Hooge, J
    Kastrukoff, L
    Krieger, C
    Mezei, M
    Seland, P
    Vorobeychi, G
    Morrison, W
    Nelson, J
    Freedman, MS
    Chrisie, S
    Nelson, R
    Rabinovitch, H
    Freedman, C
    Hartung, HP
    Rieckmann, P
    Archelos, J
    Jung, S
    Weilbach, F
    Flachenecke, P
    Sauer, J
    Hommes, O
    Jongen, P
    Brouwer, S
    McLeod, J
    Pollard, J
    Ng, R
    Sandberg-Wollheim, M
    Källén, K
    Nilsson, P
    Ekberg, R
    Lundgren, A
    Jadbäck, G
    Wikström, J
    Multanen, J
    Valjakka, M
    Carton, H
    Lissoir, F
    Declerq, I
    Vieren, M
    Peeters, E
    Dubois, B
    [J]. LANCET, 1998, 352 (9139) : 1498 - 1504
  • [7] AN ASSESSMENT OF DISABILITY RATING-SCALES USED IN MULTIPLE-SCLEROSIS
    FRANCIS, DA
    BAIN, P
    SWAN, AV
    HUGHES, RAC
    [J]. ARCHIVES OF NEUROLOGY, 1991, 48 (03) : 299 - 301
  • [8] INTERRATER AND INTRARATER SCORING AGREEMENT USING GRADES 1.0 TO 3.5 OF THE KURTZKE EXPANDED DISABILITY STATUS SCALE (EDSS)
    GOODKIN, DE
    COOKFAIR, D
    WENDE, K
    BOURDETTE, D
    PULLICINO, P
    SCHEROKMAN, B
    WHITHAM, R
    JACOBS, L
    MUNSCHAUER, F
    EMRICH, L
    GRANGER, C
    HERNDON, R
    RUDICK, R
    FISCHER, J
    SIMON, J
    SALAZAR, A
    [J]. NEUROLOGY, 1992, 42 (04) : 859 - 863
  • [9] PACED AUDITORY SERIAL-ADDITION TASK - MEASURE OF RECOVERY FROM CONCUSSION
    GRONWALL, DMA
    [J]. PERCEPTUAL AND MOTOR SKILLS, 1977, 44 (02) : 367 - 373
  • [10] Intramuscular interferon beta-1 alpha for disease progression in relapsing multiple sclerosis
    Jacobs, LD
    Cookfair, DL
    Rudick, RA
    Herndon, RM
    Richert, JR
    Salazar, AM
    Fischer, JS
    Goodkin, DE
    Granger, CV
    Simon, JH
    Alam, JJ
    Bartoszak, DM
    Bourdette, DN
    Braiman, J
    Brownscheidle, CM
    Coats, ME
    Cohan, SL
    Dougherty, DS
    Kinkel, RP
    Mass, MK
    Munschauer, FE
    Priore, RL
    Pullicino, PM
    Scherokman, BJ
    WeinstockGuttman, B
    Whitman, RH
    Baird, WC
    Fillmore, M
    Bona, LM
    ColonRuiz, ME
    Nadine, BS
    Donovan, A
    Bennett, S
    Kieffer, YM
    Umhauer, MA
    Miller, CE
    Kilic, AK
    Sargent, EL
    Schachter, M
    Shucard, DW
    Weider, V
    Catalano, BA
    Cervi, JM
    Czekay, C
    Farrell, JL
    Filippini, JS
    Matyas, RC
    Michienzi, KE
    Ito, M
    OMalley, JA
    [J]. ANNALS OF NEUROLOGY, 1996, 39 (03) : 285 - 294